Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 9Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Multiple Myeloma 2Stomach Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Colorectal Neoplasms 1Bites and Stings 1Adenocarcinoma 1

Interventions

Gemcitabine 14Cisplatin 13Capecitabine 11Paclitaxel 9Oxaliplatin 9Fluorouracil 9130-nm albumin-bound paclitaxel 9pembrolizumab 7Albumin-Bound Paclitaxel 7Ramucirumab 6Leucovorin 6Carboplatin 6Bevacizumab 6Nivolumab 5Irinotecan 5Docetaxel 5Pemetrexed 4Everolimus 4Erlotinib Hydrochloride 4Cyclophosphamide 4trastuzumab deruxtecan 3Radiotherapy 3Afatinib 3zolbetuximab 2trifluridine tipiracil drug combination 2regorafenib 2pralsetinib 2cabozantinib 2Trastuzumab 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma × dostarlimab × Clear all
NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Elevation Oncology

Phase 1 Terminated
88 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡